The Effect of Neuro Linguistic Programming on COVID-19 Fear in Kidney Transplant

November 9, 2021 updated by: Runida Dogan, Inonu University
The study was conducted experimentally to evaluate the effect of neurolinguistic programming on COVID-19 fear in kidney transplant patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study was conducted experimentally (prospective randomized single-blind clinical trial model) to evaluate the effect of neurolinguistic programming (NLP) on fear of Covid-19 in kidney transplant patients.

The study was carried out between June 2021 and October 2021. Personal Information Form and Fear of COVID-19 Scale (FCV-19S) were used to collect data. The data obtained from the research were evaluated with SPSS 25.

According to the calculation made using G*power 3.1 software, the sample size was determined as 74 (each group 37) with an effect size of 0.80, a margin of error of 0co.05, a confidence level of 0.95, and a population representation of 0.95. Simple random sampling method, one of the probability sampling methods, was used to determine the participants. Single-group columns between 1 and 300 were created using the Random Integer Generator method, which located in the Numbers sub-heading of the random.org website for the participants who met the sample selection criteria. Participants were randomly assigned to numbers 1 and 2, considering the numbers 1 and 2 in the column. The number of the experimental or control group was determined by drawing lots at the beginning of the research

Study Type

Interventional

Enrollment (Actual)

74

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Malatya, Turkey, 44100
        • Inonu University
      • Malatya, Turkey, 44100
        • inonu universitesi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:Patients who could communicate verbally, had no hearing problems, had a high or moderate fear of Covid-19 (20 or more), and had not applied NLP before were included in the study.

-

Exclusion Criteria: Patients who wanted to leave voluntarily at any stage after being included in the study, and who had to be hospitalized again for organ rejection or any other reason while the study was ongoing, were excluded from the study.

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: control group
No intervention was applied on the control group patients
Experimental: experimental group
Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change
Behavioral: neuro linguistic programming
Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
A mean total score on the
Time Frame: Fear of COVID-19 Scale . After applying the personal information form and Fear of COVID-19 Scale (FCV-19S) to the patients in the experimental group, the sub-modality technique of NLP was applied once, and then FCV-19S was applied again one week later
Fear of COVID-19 Scale (FCV-19S)
Fear of COVID-19 Scale . After applying the personal information form and Fear of COVID-19 Scale (FCV-19S) to the patients in the experimental group, the sub-modality technique of NLP was applied once, and then FCV-19S was applied again one week later

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Inonu University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2021

Primary Completion (Actual)

August 1, 2021

Study Completion (Actual)

November 1, 2021

Study Registration Dates

First Submitted

November 8, 2021

First Submitted That Met QC Criteria

November 9, 2021

First Posted (Actual)

November 10, 2021

Study Record Updates

Last Update Posted (Actual)

November 10, 2021

Last Update Submitted That Met QC Criteria

November 9, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RDNLP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

Data can be shared with the permission of the researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kidney Transplant Patients

Clinical Trials on neuro linguistic programming

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe